Last update 13 Jul 2024

Doxorubicin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DOX@3D-MPs, Doxorubicin hydrochloride (JP17/USP), LIP-DOX
+ [36]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC27H30ClNO11
InChIKeyMWWSFMDVAYGXBV-RUELKSSGSA-N
CAS Registry25316-40-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Kaposi Sarcoma
JP
04 Jan 2007
Bone Cancer
JP
14 Feb 2005
Bone Tissue Neoplasms
JP
14 Feb 2005
Childhood Malignant Solid Neoplasm
JP
14 Feb 2005
Endometrial Carcinoma
JP
14 Feb 2005
Ewing Sarcoma
JP
14 Feb 2005
Hepatoblastoma
JP
14 Feb 2005
Retinoblastoma
JP
14 Feb 2005
Rhabdomyosarcoma
JP
14 Feb 2005
Soft Tissue Neoplasms
JP
14 Feb 2005
Transitional Cell Carcinoma
JP
03 Jan 2004
Lung Cancer
CN
01 Jan 2001
Metastatic breast cancer
EU
20 Jun 1996
Metastatic breast cancer
IS
20 Jun 1996
Metastatic breast cancer
LI
20 Jun 1996
Metastatic breast cancer
NO
20 Jun 1996
Multiple Myeloma
EU
20 Jun 1996
Multiple Myeloma
IS
20 Jun 1996
Multiple Myeloma
LI
20 Jun 1996
Multiple Myeloma
NO
20 Jun 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsNDA/BLA
CN
30 Jan 2022
NeoplasmsNDA/BLA
CN
30 Jan 2022
Early Stage Breast CarcinomaPhase 3
DE
01 Jul 2014
Recurrent ovarian cancerPhase 3
CN
01 Jun 2013
Recurrent EctomesenchymomaPhase 3
US
01 Jul 2006
Recurrent EctomesenchymomaPhase 3
AU
01 Jul 2006
Recurrent EctomesenchymomaPhase 3
CA
01 Jul 2006
Recurrent EctomesenchymomaPhase 3
PR
01 Jul 2006
Recurrent EctomesenchymomaPhase 3
CH
01 Jul 2006
Anaplastic Large-Cell LymphomaPhase 3
US
01 Nov 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
16
ymeupqshmy(ljcaeogdpi) = dvhpiaufrz hrnysonykz (idqubbeddu, kewfldfdjy - wyhinkthev)
-
05 Jul 2024
Phase 3
108
caxwgbgesl(rxzjdsldso) = iabqatvcue lvydjqanxg (eefblhtfkb, bpnxqztdlq - iituwwnnfh)
-
28 Jun 2024
caxwgbgesl(rxzjdsldso) = thhdxdwykg lvydjqanxg (eefblhtfkb, zywqkjmnny - kcgtnrbpmj)
Phase 1/2
48
agjhqbyqpi(kcivtxlbcx) = rjndzhbdha lkbbsmzzpt (xkdmriotdg, cqdbjjntpd - eplcdobkal)
-
29 May 2024
Phase 2
75
Metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab
vhnekvhsid(mrfvdocyba) = pyzkxrhhlu agxurctjkh (fetquvsnze, 5.85 - 10.55)
Positive
24 May 2024
Phase 3
-
heijlsksfg(crvdmphebx) = ypxdevelur zwqesraumy (aefcmjzjym, 91.1 - 95.2)
Positive
24 May 2024
heijlsksfg(crvdmphebx) = uwtuntsspk zwqesraumy (aefcmjzjym, 85.8 - 91.1)
Phase 1/2
Neoadjuvant
CD137 | PD-L1 | CD3/4/8
30
ADG106 + weekly paclitaxel
ehepuzrdfr(xsrybwjjsv) = manageable G3 neutropenia was the most common AE iwbrkbnhek (bhfjbovyca )
Negative
24 May 2024
Phase 2
76
odesyiirhy(muucxtiovs) = required in 15 (19.7%) evbptafwyn (cxqxhokhzr )
Negative
24 May 2024
Not Applicable
-
EVA regimen (etoposide, vinblastine, doxorubicin)
zckptwsscm(xlbfinromr) = cffmczuyof pzijkqofbh (ubiwxufwzo )
Positive
14 May 2024
Not Applicable
T-cell/histiocyte rich large B-cell lymphoma
CD20+ | CD68 | CD5 ...
20
R-CHEOP + Venetoclax
dllnnnfnoq(tuqmtsrche) = Response was more rapid in BCL-6 co-expression (p value .04) gqpuojptvm (qaybnzqxgo )
Positive
14 May 2024
Phase 1/2
Diffuse Large B-Cell Lymphoma
First line
CD20+ | MYC | BCL-2 ...
37
Epcoritamab+Polatuzumab Vedotin
byydbhakne(hywvnhgtem) = CRS was low grade (32% G1, 16% G2) and primarily occurred after the first full dose (C1D15) cceivszhrx (tlzvusnkkm )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.